Research collaboration in precision medicine against cancers

KU concluded Proteo-Genome research agreement with Agilent Technologies

Joint research for development of mass spectrometry-based verification technology and extension of knowledge basis anticipated

▲ Mike McMullan, the CEO of Agilent Technologies, (left) and Lee Jinhan, the Executive Vice President for Research (right) concluded a research agreement at Korea University’s Main Hall on Tuesday, June 11, 2019.

KU concluded in the KU Main Hall on Tuesday, June 11, 2019, a research agreement with Agilent Technologies (CEO: Mike McMullan) to develop proteo-genome study-based precision medicine technologies against cancers and to extend the knowledge basis.

Based on the agreement, the Center for ProteoGenome Research (CPGR) at KU and Agilent Technologies will conduct joint research on the proteo-genome by using mass spectrometers. Both institutions will develop a mass spectrometry-based verification technology about the key cancer mechanism proteins derived from proteo-genome studies.

The CPGR at KU has been a frontier in the precise medicine technologies by developing the core technologies for investigating proteo-genome and applying them to important human diseases.

Agilent Technologies, which became an independent chemical analysis, clinical study and diagnosis division from Hewlett Packard (HP), is conducting relevant businesses in 110 countries as a leading company in the field of bioanalytical technologies.

Lee Jinhan, the Executive Vice President for Research at Korea University stated, “The combination of the proteo-genome research technologies of KU and the bioanalytical technologies of Agilent Technologies will allow various studies to be conducted and develop various analytical methods.” He also added, “The research agreement will give impetus to the development of precision medicine technologies.”